Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | AstraZeneca, Daiichi's Datroway scores its 2nd FDA approval-this time in lung cancer subset | 18 | FiercePharma | ||
Di | Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway | 3 | Seeking Alpha | ||
Di | AZ, Daiichi get Datroway nod in lung cancer on second try | 1 | pharmaphorum | ||
Di | FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer | 4 | Benzinga.com | ||
Di | AstraZeneca/Daiichi Sankyo's Datroway granted FDA accelerated approval for lung cancer | 2 | PMLiVE | ||
Di | FDA approves AstraZeneca and Daiichi Sankyo's Datroway for NSCLC | 3 | Pharmaceutical Technology | ||
DAIICHI SANKYO CO LTD ADR Aktie jetzt für 0€ handeln | |||||
Di | AstraZeneca's Precision Lung Cancer Drug Approved in US; Daiichi Sankyo to Receive Milestone Payment USD45M | 2 | AASTOCKS | ||
Di | AstraZeneca To Pay $45 Mln To Daiichi Sankyo As Datroway Gets FDA Approval For Lung Cancer | 396 | AFX News | LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed... ► Artikel lesen | |
Di | US approves AstraZeneca, Daiichi's treatment for lung cancer | 4 | Reuters | ||
07.06. | Daiichi, Shell partner for RE push | 25 | Philstar.com | ||
04.06. | Daiichi Sankyo struck gold with 'ADC' cancer drugs. Its new CEO has to figure out what's next. | 13 | BioPharma Dive | ||
02.06. | Daiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLC | 9 | Insider Monkey | ||
31.05. | AstraZeneca And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial | 1.325 | AFX News | LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced that positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU (trastuzumab deruxtecan) demonstrated... ► Artikel lesen | |
31.05. | AZN And Daiichi Sankyo's ENHERTU Shows Significant Survival Benefit In Phase 3 Gastric Cancer Trial | 4 | RTTNews | ||
30.05. | Daiichi Sankyo and MSD withdraw US application for lung cancer BLA | 3 | Pharmaceutical Technology | ||
29.05. | Merck, Daiichi pull approval application for ADC in lung cancer | 20 | BioPharma Dive | ||
29.05. | Daiichi, Merck pull HER3-DXd filing at FDA after confirmatory trial misses survival endpoint | 5 | FiercePharma | ||
29.05. | MSD and Daiichi Sankyo pull HER3-DXd's FDA filing | 3 | pharmaphorum | ||
29.05. | Merck, Daiichi Sankyo Say Biologics License Application Withdrawn For Patritumab Deruxtecan | 617 | AFX News | KENILWORTH (NJ) (dpa-AFX) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi Sankyo Company, Limited... ► Artikel lesen | |
29.05. | Merck, Daiichi Sankyo pull marketing application for lung cancer therapy | 5 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 20,665 | +0,02 % | Depot Verdoppler mit Künstlicher Intelligenz: Novo Nordisk, PanGenomic Health und Pfizer zünden 2025 den Profit-Turbo | Lauf BlackRock Health Sciences steht der globale Gesundheitssektor 2025 vor einem beispiellosen Aufschwung. Nach Jahren der Volatilität durch die Pandemie soll die Branche jetzt die höchsten Gewinnzuwächse... ► Artikel lesen | |
GILEAD SCIENCES | 94,33 | -0,18 % | Assembly Biosciences: ABI-4334 erreicht Studienziel - Gilead-Entscheidung steht bevor | Assembly Biosciences (WKN: A402CB) liefert weiter ab: Mit ABI-4334 fällt der erste wichtige Readout dieses Jahres positiv aus. Das HBV-Asset galt als das unsicherste im Portfolio. Die Aktie liebäugelt... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
VIATRIS | 7,772 | +0,54 % | Viatris Reports Positive Data From Presbyopia Study | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus... ► Artikel lesen | |
BIONANO GENOMICS | 3,260 | -0,91 % | Bionano Genomics: Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress | SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents... ► Artikel lesen | |
DAIICHI SANKYO | 19,690 | -0,88 % | AstraZeneca To Pay $45 Mln To Daiichi Sankyo As Datroway Gets FDA Approval For Lung Cancer | LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 261,50 | +1,75 % | Madrigal, Viking among notable gainers after Altimmune's MASH setback | ||
BIOHAVEN | 12,400 | +2,48 % | Biohaven Ltd.: Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor | BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases - a novel investigational therapy with the potential to treat the neuroinflammation and... ► Artikel lesen | |
MAIA BIOTECHNOLOGY | 1,695 | -1,45 % | Maia Biotechnology schließt Aktienverkaufsvereinbarung über bis zu 587.905 US-Dollar mit Prevail Partners | ||
BAYER | 26,975 | +2,64 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
23.06.2025... ► Artikel lesen | |
MERCK KGAA | 112,65 | +0,90 % | MilliporeSigma and "Abbott Elementary" Inspire Students' Curiosity With Hands-On STEM | NORTHAMPTON, MA / ACCESS Newswire / June 25, 2025 / Between September 2024 and April 2025, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, teamed up with... ► Artikel lesen | |
NOVO NORDISK | 58,70 | +0,09 % | Buy or Goodbye?: Hellofresh, Tesla, Novo Nordisk und Zalando - Die Analystenstimmen des Tages | © Foto: Steffen Trumpf/dpaHellofresh, Tesla, Novo Nordisk und Zalando: So bewerten Top-Analysten die Aktien. Ein Überblick.JPMorgan senkt das Kursziel für Hellofresh Die US-Bank JPMorgan hat das Kursziel... ► Artikel lesen | |
EYENOVIA | 10,960 | +38,91 % | Eyenovia launches validator node for Hyperliquid blockchain | ||
ROCKET LAB | 30,200 | -0,10 % | Rocket Lab Corporation: Rocket Lab to Launch Electron Mission for European Space Agency's Next-Generation Navigation System | Rocket Lab Corporation (Nasdaq: RKLB) ("Rocket Lab" or the "Company"), a global leader in launch services and space systems, today announced it has been selected to launch a dedicated Electron mission... ► Artikel lesen | |
ASTRAZENECA | 120,05 | +0,42 % | Kaum Impulse für die AstraZeneca plc-Aktie (60,9091 €) | Der Kurs der der AstraZeneca plc-Aktie kommt kaum von der Stelle. Die Aktie kostete zuletzt 70,78 US-Dollar. Die Wertschätzung der Investoren für die Aktie von AstraZeneca plc hat sich heute kaum verändert.... ► Artikel lesen |